| Pair Name | Lanatoside C, Trastuzumab | ||
| Phytochemical Name | Lanatoside C (PubChem CID: 656630 ) | ||
| Anticancer drug Name | Trastuzumab (PubChem CID: / ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Lanatoside C, Trastuzumab | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Gene Regulation | Up-regulation | Expression | ERBB2 | hsa2064 |
| In Vitro Model | NCI-N87 | Gastric tubular adenocarcinoma | Homo sapiens (Human) | CVCL_1603 |
| MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 | |
| In Vivo Model | NCI-N87 cells (5×10⁶/mouse/0.1 ml) were injected subcutaneously into the dorsal right flank of 6-week-old BALB/c nude mice. | |||
| Result | Our data suggest that combination of 131I-trastuzumab and lanatoside C might be a potential synergistic treatment for radioimmunotherapy to control the HER2 positive tumor. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model. Sci Rep. 2021 Jun 18;11(1):12871. doi: 10.1038/s41598-021-92460-0. | Click |
